Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04547413 · ClinicalTrials.gov registry record · NA
STI/HIV Intervention Behavioral Intervention Program
A NA study, sponsored by Madigan Army Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 155
- Enrollment target
NCT04547413: Completed NA study, sponsored by Madigan Army Medical Center.
NCT04547413 is a NA study that has completed, run by Madigan Army Medical Center. The registered enrollment target is 155 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04547413, a NA study, has completed, sponsored by Madigan Army Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
Study Summary
The hypothesis is that a behavioral intervention tool adapted for the US military population will be acceptable and associated with a decrease in incident sexually transmitted infection (STI)/HIV rates and high-risk sexual behaviors, and increased self-reported condom use compared to the standard of care at the Joint Base Lewis-McChord (JBLM) Preventive Medicine clinic and the Fort Bragg Department of Public Health (part of Womack Army Medical Center).
Primary Outcome
Biological testing for syphilis, chlamydia trachomatis, neisseria gonorrhea, mycoplasma genitalium, and HIV
Interventions
- BEHAVIORAL STI/HIV Intervention Behavioral Intervention Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2020-11-04 |
| Est. Completion | 2024-03-10 |
| Phase | NA |
What the finished NCT04547413 record still lists
NCT04547413 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which STI/HIV Intervention Behavioral Intervention Program is the first listed.
NCT04547413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04547413 about?
NCT04547413 is a clinical study titled "STI/HIV Intervention Behavioral Intervention Program". The hypothesis is that a behavioral intervention tool adapted for the US military population will be acceptable and associated with a decrease in incident sexually transmitted infection (STI)/HIV rates and high-risk sexual behaviors, and increased self-reported condom use compared to the standard of...
What is the current status of trial NCT04547413?
This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2020-11-04. Estimated completion is 2024-03-10.
What interventions are being tested in trial NCT04547413?
The interventions under investigation include: STI/HIV Intervention Behavioral Intervention Program (BEHAVIORAL).
Who is sponsoring clinical trial NCT04547413?
This trial is sponsored by Madigan Army Medical Center, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04547413's enrollment target sits among peer trials
155 656th of 2000 higher than 1,345 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI